10 November2026: ProBio secures exclusive global license from AbTis for next-generation ADC development
ProBio has entered into an exclusive global licensing agreement with South Korea-based AbTis, granting AbTis worldwide development and commercialization rights to a discovery-stage oncology antibody asset. AbTis plans to advance the asset toward a next-generation ADC, expanding its pipeline of bispecific ADC candidates
Under the agreement, ProBio will receive an upfront payment, potential development and commercial milestone payments, and royalties on future product sales. The financial terms, including the upfront and milestone amounts, have not been disclosed
The collaboration addresses the growing demand for differentiated ADC candidates, combining antibody discovery capabilities with specialized conjugation technology to generate new oncology assets. The licensed candidate remains at the discovery stage, with no clinical data or development timeline disclosed
AbTis will leverage its proprietary AbClick site-specific conjugation platform to develop the ADC. The technology enables controlled attachment of linker-payloads at defined antibody sites, aiming to improve conjugate homogeneity and consistency compared with conventional non-specific conjugation approaches. The companies have not disclosed the antibody target, payload or linker chemistry for this program
Strategically, the deal strengthens AbTis’ pipeline-building strategy in bispecific ADCs while validating ProBio’s ability to generate licensable therapeutic antibody assets beyond its conventional CRDMO services